Menu

Search

  |   Business

Menu

  |   Business

Search

MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018, at 2:30 p.m. PT (5:30 p.m. ET) in San Francisco.

A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases.  MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.  MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial.  MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers.  A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.

Contacts

Beth DelGiacco (Investors)
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Steven Cooper (Media) 
Edelman
415-486-3264
[email protected]

Primary Logo

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

2018-01-18 16:31:10
0m

January 18 16:00 UTC Released

USEIA Weekly Heatoil Stock

Actual

0.084 M

Forecast

Previous

-0.769 M

January 18 16:00 UTC Released

USEIA Weekly Crude Runs

Actual

-0.448 M

Forecast

Previous

-0.285 M

January 18 21:30 UTC 226226m

NZManufacturing PMI

Actual

Forecast

Previous

57.7 0

January 19 07:00 UTC 796796m

DEProducer Prices MM

Actual

Forecast

Previous

0.1 %

January 19 07:00 UTC 796796m

DEProducer Prices YY

Actual

Forecast

Previous

2.5 %

January 19 08:00 UTC 856856m

HUGross Wages YY

Actual

Forecast

Previous

12.8 0

January 19 09:00 UTC 916916m

EZCurrent Account NSA,EUR

Actual

Forecast

Previous

35.9 Bln EUR

January 19 09:00 UTC 916916m

EZCurrent Account SA, EUR

Actual

Forecast

Previous

30.8 Bln EUR

January 19 09:30 UTC 946946m

GBRetail Sales MM

Actual

Forecast

Previous

1.1 %

January 19 09:30 UTC 946946m

GBFuel MM

Actual

Forecast

Previous

1.2 %

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.